Introduction: The relationship between the immune-active states of chronic hepatitis and inflammatory bowel disease (IBD) is under explored. Immunosuppressants given for IBD may worsen viral burden, and viral-induced immune system activation may worsen the effects of IBD. Recent epidemiologic surveys have shown the prevalence of Hepatitis B and C infections in IBD patients is similar to that of the general population, but the effect of chronic hepatitis on outcomes in IBD patients is not well defined. We aim to determine the epidemiology and outcomes of chronic hepatitis B (CHBV) and hepatitis C (CHCV) in hospitalized individuals with Crohn's disease (CD) and ulcerative colitis (UC) using a large nationwide inpatient database spanning nearly two decades.2810_A Figure 1. Prevalence of chronic HBV, chronic HCV, infections per 1000 patient hospitalizations (IBD population) from 1998 to 2014Methods: The National Inpatient Sample (NIS) was used to identify patients with CD, UC, CHBV, CHCV during the years 1998-2014 using corresponding ICD-9-CM codes. The prevalence of CHBV or CHCV infections per 1000 patient hospitalizations in CD and UC populations was calculated. Linear and logistic regression were used to estimate the effect of CHBV and CHCV on the outcomes of death, venous thromboembolism, malnutrition, acute kidney injury (AKI), sepsis, bowel resection, length of stay (LOS) and total charges (TC). Multivariable models were controlled for age, gender, race, payer, income quartile, hospital size and teaching status, region, and Charlson comorbidity score.2810_B Figure 2. Baseline characteristics of patient hospitalizations (IBD population) in chronic HBV, chronic HCV, and control subsets2810_C Figure 3. Adjusted odds ratios for chronic HBV, chronic HCV, on healthcare outcomes controlling for age, gender, race, payer, income quartile by zip code, hospital size, hospital teaching status, region, and Charlson comorbidity indexResults: We identified 3.87 million IBD patients with baseline characteristics listed in table 1. The annual incidence of CHCV increased at a higher rate than that of CHBV (figure 1). Multivariate outcomes are listed (table 2). CHBV was associated with increased mortality and sepsis among UC patients, but did not show a significant impact on outcomes among the CD population. CHCV was associated with increased mortality, AKI, sepsis, and surgery in both IBD groups. CHBV and CHCV were associated with increased LOS and TC among CD, but not UC patients Conclusion: The prevalence of CHCV infection in hospitalized IBD patients has risen significantly from 1998 to 2014, while the prevalence of CHBV has remained stable. Patients with CHCV and IBD have an increased risk of death, AKI, sepsis, and colon surgery, while CHBV carries an increased risk of mortality and sepsis among UC patients. Both types of chronic hepatitis increased LOS and TC among the CD population. Further investigation is needed into the mechanisms of CHBV or CHCV leading to adverse outcomes in IBD patients.